Formulating for the Future of Transplant Patient Therapy

Transplant Support

Veloxis is a specialty pharmaceutical company committed to improving the lives of transplant patients. Our unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs.

Veloxis Pharmaceuticals A/S is headquartered Copenhagen, DK and operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.

Veloxis is committed to patient access and financial support for kidney transplant patients. Learn more about our prescription cost savings programs, click here Go to


Nov 15, 2017
Q3 Report 2017 Investor Call

Webcast Webcast

Conference call at 4:00 pm CET

Please dial in 5-10 minutes prior to the start time using the number / Conference ID below.

Confirmation Code: 4943899

Denmark:  +4532 71 16 59

United Kingdom: +44(0)20 3427 1907

United States of America: +1646 254 3362

Stock Information